Please login to the form below

amyotrophic lateral sclerosis

This page shows the latest amyotrophic lateral sclerosis news and features for those working in and with pharma, biotech and healthcare.

FDA grants priority review to Biogen’s tofersen for genetic form of ALS

The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Biogen’s tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral ... sclerosis (ALS).

Latest news

Six UK universities receive grant for research into motor neurone disease

MND (also known as amyotrophic lateral sclerosis, or ALS) is an uncommon neurodegenerative disease which affects the brain and nerves, causing weakness that gets progressively worse over time.
SOLVE FSHD announces the appointment of Dr Eva Chin as its executive director

Dr Chin has been responsible over the last five years for overseeing the non-clinical development of numerous drug candidates in clinical trials for amyotrophic lateral sclerosis (ALS), spinal muscular atrophy
Biogen's ALS drug tofersen misses phase 3 endpoint

Biogen has announced that its antisense drug tofersen has failed to meet its primary endpoint in the phase 3 VALOR trial involving people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis
GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

As part of the deal, GSK and Alector will develop AL001 and AL101 for a range of these disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s ... amyotrophic lateral sclerosis (ALS) in the
Biogen to open compassionate use programme for ALS patients with ‘rapidly progressive disease’

Move comes after mounting pressure from patients and campaigners. Biogen has announced that it will offer its investigational drug tofersen to patients with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)

More from news
Approximately 2 fully matching, plus 52 partially matching documents found.

Latest Intelligence

Alzheimer’s disease: the search for a cure

The Dementia Consortium funds research into novel targets and treatments for dementia including Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, plus Parkinson’s disease, amyotrophic lateral sclerosis and
Perfecting the pharmaceutical pipeline with AI

In fact, this has helped our team of scientists at BenevolentBio establish a set of hypotheses for drug candidates for Amyotrophic Lateral Sclerosis (ALS), a form of Motor Neurone Disease.
Deal Watch July 2016

181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and generation skeletal muscle activators in amyotrophic lateral sclerosis.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals

The US-based pharmaceutical firm specialises in developing disease-modifying treatments for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS).
Biogen Idec appoints senior neuroscientists

The two will help lead Biogen Idec's research efforts across neurodegenerative and neuroimmune diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). ... He was also professor of
Biogen Idec names ALS unit head

Donald Johns joins from Novartis. Biogen Idec has named former Novartis scientist Dr Donald Johns as head of its innovation hub for amyotrophic lateral sclerosis (ALS).
Andrew Gengos joins ImmunoCellular as CEO

ImmunoCellular will benefit from Gengos's experience in neuroscience during his time at Neuraltus, which specialises in therapies for neurodegenerative diseases, such as amyotrophic lateral sclerosis and Parkinson's disease.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

The ALS patient journey

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). ... That will be the start of ALS, but your doctor will want to rule out other things, for example, Parkinson’s disease or multiple sclerosis.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.